<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04230356</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1217</org_study_id>
    <nct_id>NCT04230356</nct_id>
  </id_info>
  <brief_title>Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant</brief_title>
  <official_title>A Randomized Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells (VSTs) for Control of Viral Infections After Allogeneic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoxworth Blood Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn more about the use of viral specific&#xD;
      T-lymphocytes (VSTs) to treat viral infections that may happen after allogeneic stem cell&#xD;
      transplant. Allogeneic means the stem cells come from another person. VSTs are cells&#xD;
      specially designed to fight viral infections that may happen after a stem cell transplant&#xD;
      (SCT).&#xD;
&#xD;
      Stem cell transplant reduces the body's ability to fight infections. Viral infections are a&#xD;
      common problem after transplant and can cause significant complications. Moreover, treatment&#xD;
      of viral infections is expensive and time consuming, with families often administering&#xD;
      prolonged treatments with intravenous anti-viral medications, or patients requiring prolonged&#xD;
      admissions to the hospital. The medicines can also have side effects like damage to the&#xD;
      kidneys or reduction in the blood counts, so in this study the investigators are trying to&#xD;
      find a better way to treat these infections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment Failures</measure>
    <time_frame>21 - 100 days after transplant</time_frame>
    <description>Treatment failure is defined as EBV&gt;100,000, BKV &gt;100,000, CMV &gt;5,000 or Adv &gt;50,000 at any time post randomization.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Allogeneic Stell Cell Transplant</condition>
  <condition>Viral Infection</condition>
  <arm_group>
    <arm_group_label>VSTs to Prevent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VSTs are given through an IV infusion 21 days after transplant to see if the VSTs will help prevent a viral infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VSTs to Treat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VSTs will be given only if a viral infection develops.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Viral Specific T-cells (VSTs) Scheduled</intervention_name>
    <description>VSTs will be infused into stem cell transplant recipients on schedule.</description>
    <arm_group_label>VSTs to Prevent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Viral Specific T-cells (VSTs) Treatment</intervention_name>
    <description>VSTs will be infused into stem cell transplant recipients only if viremia is detected.</description>
    <arm_group_label>VSTs to Treat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        SCHEDULED ARM:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipient must be at least 21 days after stem cell infusion&#xD;
&#xD;
          -  Clinical status must allow tapering of any steroids to &lt; 0.5mg/kg prednisone or other&#xD;
             steroid equivalent&#xD;
&#xD;
          -  No critical illness making VST infusion hazardous&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active acute GVHD grades II-IV.&#xD;
&#xD;
          -  Uncontrolled relapse of malignancy.&#xD;
&#xD;
          -  Infusion of ATG or alemtuzumab within 2 weeks of VST infusion. Alemtuzumab levels will&#xD;
             be collected in the second week following stem cell infusion in patients who received&#xD;
             alemtuzumab as part of their conditioning regimen. The level must be less than or&#xD;
             equal to 0.15 prior to infusion of VSTs. In patients with level greater than 0.15,&#xD;
             alemtuzumab levels can be checked serially until a level ≤ 0.15 is obtained. They&#xD;
             would become eligible for scheduled VST infusion at that point.&#xD;
&#xD;
        TREATMENT ARM&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Blood adenovirus PCR ≥1,000&#xD;
&#xD;
          -  Blood CMV PCR ≥ 500&#xD;
&#xD;
          -  Blood EBV PCR ≥ 9,000&#xD;
&#xD;
          -  Plasma BKV PCR &gt;1,000&#xD;
&#xD;
          -  Evidence of invasive adenovirus infection. Adenovirus infection will be defined as the&#xD;
             presence of adenoviral positivity as detected by PCR or culture from one site such as&#xD;
             stool or blood or urine or nasopharynx. Adenovirus disease will be defined as the&#xD;
             presence of adenoviral positivity as detected by culture or PCR from more than 2 sites&#xD;
             such as stool or blood or urine or nasopharynx.&#xD;
&#xD;
          -  Evidence of invasive CMV infection, e.g. pneumonitis, retinitis, colitis&#xD;
&#xD;
          -  Evidence of EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by&#xD;
             biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood&#xD;
             associated with clinical symptoms (adenopathy or fever or masses on imaging) but&#xD;
             without biopsy confirmation.&#xD;
&#xD;
          -  Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic&#xD;
             cystitis&#xD;
&#xD;
          -  No active acute GVHD grades II-IV&#xD;
&#xD;
          -  No uncontrolled relapse of malignancy&#xD;
&#xD;
          -  No infusion of ATG or alemtuzumab within 2 weeks of VST infusion.&#xD;
&#xD;
          -  Clinical status must allow tapering of any steroids to &lt; 0.5mg/kg prednisone or other&#xD;
             steroid equivalent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stella Davies, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Celeste Dourson, MS</last_name>
    <phone>513-636-7679</phone>
    <email>Celeste.Dourson@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jamie Wilhelm, BS</last_name>
    <phone>513-803-1102</phone>
    <email>Jamie.Wilhelm@cchmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celeste Dourson, MS</last_name>
      <phone>513-636-7679</phone>
      <email>Celeste.Dourson@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Stella Davies, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

